| Date | Title | Description | Source |
| 14.03.2024 | Rare Disease Advocates Learn to Accelerate Therapeutic Devel... | RARE Drug Development Symposium
The RARE Drug Development Symposium, hosted by Global Genes and the ... | prweb.com/... |
| 12.03.2024 | Clearside Biomedical Announces Fourth Quarter and Full Year ... | - Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 -
- Partner ... | einpresswi... |
| 05.03.2024 | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule... | - | globenewsw... |
| 05.01.2024 | BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (ber... | —ORLADEYO preliminary 2023 full year net revenue of $325 million (+29 percent y-o-y)—
—ORLADEYO net ... | einpresswi... |
| 05.01.2024 | BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (ber... | - | globenewsw... |
| 18.04.2023 | BioCryst Refinances Existing Debt with $450 Million Financin... | - | globenewsw... |
| 11.01.2022 | BioCryst Announces Preliminary Full Year 2021 ORLADEYO (bero... | RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced preliminary, u... | marketscre... |
| 10.01.2022 | BioCryst Announces Preliminary Full Year 2021 ORLADEYO® (ber... | —ORLADEYO preliminary net revenue of $45.6 million for Q4 2021 and $122 million for FY 2021—
—ORLADE... | marketscre... |
| 22.11.2021 | BioCryst Adds $350 Million in New Financing with Royalty Pha... | —Provides funding for BCX9930/oral Factor D program across multiple indications—
—Agreements support... | globenewsw... |
| 22.11.2021 | BioCryst Adds $350 Million in New Financing with Royalty Pha... | —Provides funding for BCX9930/oral Factor D program across multiple indications—
—Agreements support... | marketscre... |
| 22.11.2021 | BioCryst gets massive cash infusion to the tune of $350M,... | BioCryst is filling its coffers again — this time in $350 million cash with the help of both old ... | endpts.com... |
| 03.11.2021 | BioCryst Third Quarter 2021 Conference Call | Third Quarter 2021 Results Call
Corporate Update & Financial Results
November 3, 2021
Forward-Lo... | marketscre... |
| 06.05.2021 | BIOCRYST PHARMACEUTICALS, INC.
BioCryst Pharmaceuticals : F... | First Quarter 2021 Results Call
Corporate Update & Financial Results
May 6, 2021
Forward-Looking... | marketscre... |
| 06.08.2020 | BIOCRYST PHARMACEUTICALS, INC.
BioCryst Reports Second Quar... | —ORLADEYO™ (berotralstat) approvals expected in U.S. and Japan in Q4 2020, EU in early 2021—
—200 mg... | marketscre... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Figh... | Alain Mérieux, founder of BioMérieux.AFP via Getty Images | forbes.com... |
| 14.03.2012 | BCRX challenges Biota patent, claims its hepatitis C compoun... | BioCryst says BCX 5191 is a compound that was discovered within its labs. Being the first to discove... | medcitynew... |
| 17.02.2012 | Contract drug manufacturer Patheon names former BCRX executi... | Grant comes to Patheon as the company adjusts its business strategy. Last year, the company announce... | medcitynew... |
| 15.02.2012 | Hepatitis C compound from BioCryst set for 4Q IND filing | While Durham, North Carolina-based BioCryst plans to conduct early stage clinical trials for its hep... | medcitynew... |
| 18.01.2012 | #JPM12 takeaway: Big Pharma puts a big hurt on primary care | But beyond the canned corporate remarks, there were some insights to be made. Shane Climie of consul... | medcitynew... |
| 11.10.2011 | Former Roche executive Abercrombie named to BioCryst board | Abercrombie, who has more than 30 years of experience in the pharmaceutical industry, takes the plac... | medcitynew... |
| 05.10.2011 | BCRX gout drug looks good in phase 2, but Ardea’s drug looks... | Durham, North Carolina-based BioCryst released positive phase 2b trial results from a 12-week study ... | medcitynew... |
| 26.05.2011 | Drug partnering as strategy: How BioCryst plans to move its ... | BCX4208 is a partner candidate. Most gout patients are treated with allopurinol. Available in the Un... | medcitynew... |
| 25.05.2011 | Former Inspire executive Staab named new BioCryst CFO | Inspire was recently acquired by Merck (NYSE:MRK) for $430 million. That deal followed Inspire’s fai... | medcitynew... |
| 04.05.2011 | BioCryst invests $5M into pipeline that includes gout, hepat... | The experimental gout drug is called BCX4208. The compound is already in mid-stage clinical trials, ... | medcitynew... |
| 29.03.2011 | North Carolina pharma R&D funding: A snapshot of 2010 | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis h... | medcitynew... |
| 10.03.2011 | Drug developer BioCryst raises $30M | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems stri... | medcitynew... |
| - | Hepatitis C compound from BioCryst set for 4Q IND filing | The investigational hepatitis C treatment under development by BioCryst Pharmaceuticals (NASDAQ:BCRX... | medcitynew... |
| - | Drug developer BioCryst raises $30M | Drug developer BioCryst Pharmaceuticals has secured $30 million in financing it will use to continue... | medcitynew... |
| - | Contract drug manufacturer Patheon names former BCRX executi... | Contract drug manufacturer Patheon (TSX:PTI) has a new chief financial officer, one who is no strang... | medcitynew... |
| - | BCRX gout drug looks good in phase 2, but Ardea’s drug looks... | The investigational gout treatment being developed by BioCryst Pharmaceuticals (NASDAQ:BCRX) aims to... | medcitynew... |
| - | Drug partnering as strategy: How BioCryst plans to move its ... | BioCryst Pharmaceuticals CEO Jon Stonehouse got a jump on Memorial Day weekend travel. Today, Stoneh... | medcitynew... |
| - | BioCryst invests $5M into pipeline that includes gout, hepat... | BioCryst Pharmaceuticals (NASDAQ:BCRX) got its hands on some big dollars in the first three months o... | medcitynew... |
| - | #JPM12 takeaway: Big Pharma puts a big hurt on primary care | The JP Morgan Annual Healthcare Conference has become the biggest conference for the industry drawin... | medcitynew... |
| - | Former Roche executive Abercrombie named to BioCryst board | Former Roche executive George Abercrombie has been elected to BioCryst Pharmaceuticals‘ (NASDAQ:BCRX... | medcitynew... |
| - | North Carolina pharma R&D funding: A snapshot of 2010 | Research and development spending dollars reached a record $67.4 billion in 2010, a $1.5 billion inc... | medcitynew... |
| - | Former Inspire executive Staab named new BioCryst CFO | BioCryst Pharmaceuticals (NASDAQ:BCRX) has hired former Inspire Pharmaceuticals executive Tom Staab ... | medcitynew... |
| - | BCRX challenges Biota patent, claims its hepatitis C compoun... | The experimental hepatitis C treatment that BioCryst Pharmaceuticals (NASDAQ:BCRX) wants to take int... | medcitynew... |
